Can I read An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain on EtoBox?

An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain by Kenji Onouchi; Kazumasa Yokoyama; Tamotsu Yoshiyama; Hiroaki Koga is a scholarly article available to read on EtoBox.

What is An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain about?

## Purpose Studies of pregabalin for the treatment of central neuropathic pain have been limited to double-blind trials of 4–17 weeks in duration. The purpose of this study was to assess the long-term safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. The efficacy of pregabalin was also assessed as a secondary measure. ## Patients and methods This was a 53-week, multicenter, open-label trial of pregabalin (150–600 mg/day) in Japanese patients with central neuropathic pain due to spinal cord injury, multiple sclerosis, or cerebral stroke. ## Results A total of 103 patients received pregabalin (post-stroke =60; spinal cord injury =38; and multiple sclerosis =5). A majority of patients (87.4%) experienced one or more treatment-related adverse events, most commonly somnolence, weight gain, dizziness, or peripheral edema. The adverse event profile was similar to that seen in other indications of pregabalin. Most treatment-related adverse events were mild (89.1%) or moderate (9.2%) in intensity. Pregabalin treatment improved total score, sensory pain, affective pain, visual analog scale (VAS), and present pain intensity scores on the Short-Form McGi

Author

Kenji Onouchi; Kazumasa Yokoyama; Tamotsu Yoshiyama; Hiroaki Koga

Publisher

Informa UK Limited

Published

2014

Language

EN